CVS Health Reports Strong Q3 2026 Results and Raises Full-Year Guidance
CVS Health (CVS) reported robust third-quarter 2026 financial results, characterized by a 5.4% revenue increase to $108.4 billion and an adjusted EPS of $2.09, representing over 30% year-over-year growth. The company's performance was bolstered by strong results in the Health Services and Health Care Benefits segments, alongside a significant 23% growth in GLP-1 prescriptions. Driven by these results, management raised its full-year adjusted EPS guidance to at least $8.20 and increased its cash flow from operations expectations to at least $15.5 billion. While the company faces headwinds such as declining commercial business revenue due to an exit from individual exchanges and industry-wide elevated medical costs, it plans to resume share repurchases in the fourth quarter after reaching leverage targets ahead of schedule.
Tickers: $CVS
Topics: EPS beat GLP-1 prescriptions guidance raise healthcare services revenue growth